Carlisle JW, Steuer CE, Owonikoko TK, Saba NF. An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin. 2020:70:505‐517.

On page 2, 1^st paragraph under Non–Small Cell Lung Cancer: Advanced/Metastatic Disease, reference #4 should be moved to the end of the 3^rd sentence as follows:

Thus nivolumab, pembrolizumab, and atezolizumab were approved based on results of the CheckMate 017 (ClinicalTrials.gov identifier NCT16420054), CheckMate 057 (ClinicalTrials.gov identifier NCT01673867), KEYNOTE‐010 (ClinicalTrials.gov identifier NCT01905657), and OAK (ClinicalTrials.gov identifier NCT02008227) trials, respectively.^4‐8

Carlisle JW、Steuer CE、Owonikoko TK、Saba NF。肺癌和头颈癌免疫状况的最新进展。CA癌症J临床。2020:70:505-517。

在第2页1周^ST下非小细胞肺癌的段落：高级/转移性疾病，参照＃4应当移动到3的端^RD句子如下所示：

因此，nivolumab、pembrolizumab 和 atezolizumab 根据 CheckMate 017（ClinicalTrials.gov 标识符 NCT16420054）、CheckMate 057（ClinicalTrials.gov 标识符 NCT01673867）、KEYNOTE-010（ClinicalCTTrials.5905ClinicalTrials.5905ClinicalTrials.gov54 标识符）的结果获得批准。 gov 标识符 NCT02008227) 试验，分别。^4-8